Recent studies have emphasized the therapeutic potential of targeting ferroptosis-related pathways, such as system Xc− inhibition and GPX4 degradation, for overcoming therapy resistance and suppressing metastasis in lung cancer (Xia et al., 2019; Kim et al., 2023; Fan et al., 2025). The gene discussed is GPX4; the disease is lung carcinoma.